论文部分内容阅读
本文对1972年1月～1977年12月连续诊断的32例成人(12岁以上)“急淋”的临床和血液学特征以及对治疗的反应进行了研究。并对该32例和另外作者报告的106例“急淋”影响预后的几个临床和血液学因素进行了分析。全部32例给予 VP 方案(长春新硷、强的松龙)诱导治疗。9例经3个剂量的长春新硷治疗后,骨髓和血液中的原始细胞没有被清除,加用3个剂量的红比霉素(D)。周围血原始细胞多于25,000/μl 或纵隔障受累、B 或 T 细胞型白血病、或巨大的肝脏和脾脏的9例给予更强烈的化疗,即在诱导治疗开始时除VP 外再给予单剂量的环磷酰胺(C)以及在第3周给予3个剂量的红比霉素。完全缓解10天内给予中枢
In this paper, the clinical and hematological characteristics of 32 acute lymphoblastic (over 12 years old) patients diagnosed consecutively from January 1972 to December 1977 were studied and the response to treatment was studied. And analyzed the clinical and hematological factors of 106 cases of acute lymphoblastic prognosis reported by 32 cases and other authors. All 32 patients were given VP regimen (vincristine, prednisolone) induction therapy. After 9 doses of vincristine at 3 doses, the blasts in the bone marrow and blood were not cleared and 3 doses of doxorubicin (D) were added. Nine cases of peripheral blood blasts with more than 25,000 / μl or mediastinal involvement, B or T-cell leukemia, or massive liver and spleen were given more intensive chemotherapy, ie, a single dose of VP was administered at the beginning of induction therapy Cyclophosphamide (C) and 3 doses of rubhamomycin at week 3. Complete remission within 10 days to the center